Skip to content
‹ Back to IndustriesHealthcare

Surfacide experiences 500% Increase in Demand of Their Coronavirus Killing UV Robots

(Waukesha, WI)—January 5, 2021 – Surfacide®, the leader in hospital-grade, triple-emitter UV-C robot technology, is excited to announce they’ve moved to a larger facility in Waukesha, WI to accommodate rapid business growth at more than 500% in the past year. As we move into our new normal, germ-fighting, COVID-19 killing “robots” is being deployed everywhere…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

·
Share
Surfacide experiences 500% Increase in Demand of Their Coronavirus Killing UV Robots

Free workspace

Turn your Healthcare expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

(Waukesha, WI)—January 5, 2021 – Surfacide®, the leader in hospital-grade, triple-emitter UV-C robot technology, is excited to announce they’ve moved to a larger facility in Waukesha, WI to accommodate rapid business growth at more than 500% in the past year. As we move into our new normal, germ-fighting, COVID-19 killing “robots” is being deployed everywhere from hospitals, nursing homes, restaurants, hotels, gyms to commercial office spaces, tourist attractions, and professional sports stadiums. Surfacide has been a trusted leader in UV decontamination for over ten years due to its world’s only patented Helios® Triple-Emitter System of three virus-zapping robots.

Surfacide is actively being used throughout the world in over 500 leading healthcare facilities, children’s hospitals, nursing homes, correctional facilities, dental offices, hotels, restaurants, commercial businesses and more around the world. Such facilities include the Seattle Space Needle, Beachbody Studios, Children’s Hospital of Los Angeles and locally at Children’s Hospital of Wisconsin, Froedtert Medical College—Milwaukee and Aspirus Wausau Hospital. The company’s UV-C technology is scientifically validated to inactivate coronavirus–the family of virus that make up SARS-CoV-2 and COVID-19.

Surfacide’s new location is at N918 Northmound Dr., STE. 300 Waukesha, WI 53186 and the company’s new facility is more than 75,000 sq-ft, three times the size of their previous location. The company was started in a one-room office in 2010 and has experienced incredible and consistent growth every year since its inception. The expansive new building space will offer much needed space for Surfacide’s expanding team and to meet the huge increase in demand for their UV system since the pandemic hit. The facility will continue to house the company’s manufacturing and distribution arm, as well as a global training center, a state-of-the-art UV robot simulation room, conference rooms and offices.

Gunner Lyslo, Founder & CEO of Surfacide shares his excitement for the new space: “During the pandemic, we are fortunate to have grown our team and provide a proven UV-C technology that has tremendously impacted healthcare facilities, nursing homes, dental offices, and more in fighting the COVID-19 virus,” says Lyslo. “This year the importance of infection prevention has been paramount, and we expect to see that course continue in years to come. For as long as our communities need safety and protection, Surfacide will continue to evolve and be there to assist those who need it most.”

 About Surfacide

 Surfacide LLC and Surfacide Manufacturing Inc. are located in Waukesha, WI and produce multiple emitter UV-C systems. Surfacide is the only patented triple emitter UV-C system, providing the most efficient and flexible solution in the fight against viruses and bacteria that cause hospital-acquired infections. Hundreds of hospitals worldwide are using Surfacide technology to provide an extra layer of protection for patients and healthcare workers. Surfacide’s evidence-based UV-C solution reaches more surfaces, reduces shadowed areas, and requires less labor for a quicker turnaround time and better efficacy. Learn more about Surfacide by visiting https://surfacide.com or calling (844)-390-3538.

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Book DemoSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Healthcare Insights

Why hospitals stagger security upgrades instead of shutting down

Why hospitals stagger security upgrades instead of shutting down

Parabit Systems' Robert Iraggi told A Weekly Bit that hospital security upgrades must be planned and staggered because the building never closes. OSHA counted 7.8 serious violent injuries per 10,000 healthcare workers in 2013 against under two in construction, and Joint Commission EP 17 requires an annual worksite analysis. Illinois biometric law adds a consent step for facial recognition.

  • 01OSHA counted 7.8 serious violent injuries per 10,000 healthcare workers in 2013; construction, manufacturing and retail each stayed under two.
  • 02Joint Commission EP 17 has required an annual workplace violence worksite analysis since January 2022, and hospitals are expected to act on what it finds—making phased security upgrades easier to document year to year.
  • 03Squire Patton Boggs counted at least 100 Illinois biometric privacy class actions filed in 2025, and Illinois’ BIPA requires notice and consent for collecting biometrics—so a facial-recognition rollout plan should include the notice, consent record, and retention controls before the first camera goes live.

Nov 17, 2026

Sterile processing deviations become the norm without stop-and-document rules

Sterile processing deviations become the norm without stop-and-document rules

Advanced Sterilization Products' Tamara Beeler told Censis Technologies' CtUC 2026 audience that sterile processing deviations harden into norms when departments don’t stop, escalate and document them. She connects ANSI/AAMI ST108:2023 water categories, daily cleaning verification, loaner-tray refusal when sets arrive late or lack IFUs, and root cause analysis when rework repeats on the same device.

  • 01ANSI/AAMI ST108:2023 turned water quality for instrument reprocessing into an enforceable standard; AAMI's earlier TIR34 was guidance with no enforcement behind it.
  • 02Some facilities require loaner trays 48 hours before a case, and ASP's Tamara Beeler says a technician at any level can refuse one that arrives late, undocumented or dirty.
  • 03Rework that returns on the same device is the point at which Beeler wants a root cause analysis opened, with the record kept in the instrument tracking system.

Nov 17, 2026

TheraPanacea aims to spread best-center radiotherapy quality

TheraPanacea aims to spread best-center radiotherapy quality

TheraPanacea CEO Nikos Paragios says the company's two objectives are to carry best-center radiotherapy quality to every patient and to pick each patient's treatment at the start from multimodal data. A 2026 Nature Communications trial of 500 patients found AI-assisted contouring lifted mean Dice overlap from 0.857 to 0.902, and Siemens Healthineers CE-marked its own AI contouring in May 2026.

  • 01TheraPanacea's two stated objectives: carry best-center radiotherapy quality to every patient on the globe, and identify each patient's best treatment at the start from imaging and clinical history.
  • 02A 2026 Nature Communications trial of 500 patients across five centers found AI-assisted contouring lifted mean Dice overlap from 0.857 to 0.902 and cut median contouring time from 55 to 10 minutes, with less variation between centers.
  • 03Siemens Healthineers' Varian business CE-marked AI contouring for Eclipse in May 2026, so Paragios locates TheraPanacea's edge in its team, hospital partnerships and impact focus rather than in the algorithm alone.

Nov 17, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512